These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 23537411)
1. [Introduction to novel vaccine adjuvants and their role in influenza vaccination]. Haensler J Ann Pharm Fr; 2013 Mar; 71(2):104-8. PubMed ID: 23537411 [TBL] [Abstract][Full Text] [Related]
2. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847 [TBL] [Abstract][Full Text] [Related]
4. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829 [TBL] [Abstract][Full Text] [Related]
5. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470 [TBL] [Abstract][Full Text] [Related]
6. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330 [TBL] [Abstract][Full Text] [Related]
8. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049 [TBL] [Abstract][Full Text] [Related]
9. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population. Thongcharoen P; Auewarakul P; Hutagalung Y; Ong G; Gillard P; Drame M; Bock HL J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672 [TBL] [Abstract][Full Text] [Related]
10. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945 [TBL] [Abstract][Full Text] [Related]
11. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709 [TBL] [Abstract][Full Text] [Related]
13. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222 [TBL] [Abstract][Full Text] [Related]
14. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations]. de Jong JC; Osterhaus AD Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026 [TBL] [Abstract][Full Text] [Related]
15. NEW technologies for meeting the global demand for pandemic influenza vaccines. Fedson DS Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454 [TBL] [Abstract][Full Text] [Related]
17. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Leroux-Roels G Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313 [TBL] [Abstract][Full Text] [Related]
18. Aflunov(®): a prepandemic influenza vaccine. Gasparini R; Amicizia D; Lai PL; Panatto D Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663 [TBL] [Abstract][Full Text] [Related]
19. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection. Jones T Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]